Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,987 result(s) found. Displaying page 347 of 550.
    «« First « Previous 343  344  345  346  347  348  349  350  351  Next» Last»»
    EudraCT Number: 2019-003826-25 Sponsor Protocol Number: G1T28-207 Start Date*: 2020-12-08
    Sponsor Name:G1 Therapeutics, Inc.
    Full Title: PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
    Medical condition: Prevention of chemotherapy-induced myelosuppression in patients receiving FOLFOXIRI/bevacizumab for mCRC
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    23.1 100000004851 10028585 Myelosuppression adult LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) PL (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004561-13 Sponsor Protocol Number: ISIS420915-CS3 Start Date*: 2014-07-04
    Sponsor Name:Ionis Pharmaceuticals, Inc
    Full Title: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP)
    Medical condition: Familial Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000452-18 Sponsor Protocol Number: ETB115J2411 Start Date*: 2018-09-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (...
    Medical condition: immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    22.1 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GR (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003098-24 Sponsor Protocol Number: CLCZ696I12201 Start Date*: 2019-12-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardio...
    Medical condition: non-obstructive hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004519-43 Sponsor Protocol Number: NN18344 Start Date*: 2005-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000353-38 Sponsor Protocol Number: WX-2003-07-HR Start Date*: 2004-12-20
    Sponsor Name:Wilex AG
    Full Title: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence
    Medical condition: Renal cell carcinoma of the clear cell type after nephrectomy and no evidence of residual disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) GB (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004212-21 Sponsor Protocol Number: AMAG-423-201 Start Date*: 2019-05-24
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree...
    Medical condition: Severe Preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002804-29 Sponsor Protocol Number: PA0011 Start Date*: 2019-06-26
    Sponsor Name:UCB Biopharma SRL
    Full Title: A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-001608-12 Sponsor Protocol Number: IOV-COM-202 Start Date*: 2019-06-06
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
    Medical condition: Solid Tumours including advanced unresectable or metastatic melanoma (MM), advanced squamous cell carcinoma of the head and neck (HNSCC) and non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003649-10 Sponsor Protocol Number: CA40192 Start Date*: 2018-03-13
    Sponsor Name:Roche Farma S.A. (Soc unipersonal) que realiza el ensayo en España y que actúa como represntante de FHoffmann-La Roche
    Full Title: A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LES...
    Medical condition: Moderate to severe ulcerative colitis (UC); moderate to severe Crohn’s disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) DE (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002214-31 Sponsor Protocol Number: XmAb5871-06 Start Date*: Information not available in EudraCT
    Sponsor Name:Xencor, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)
    Medical condition: IgG4-Related Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10071581 IgG4 related sclerosing disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003212-36 Sponsor Protocol Number: ACE-WM-001 Start Date*: 2014-12-09
    Sponsor Name:Acerta Pharma BV
    Full Title: An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia
    Medical condition: Waldenström Macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047804 Waldenstrom's macroglobulinaemia recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047805 Waldenstrom's macroglobulinaemia refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000381-11 Sponsor Protocol Number: CCMK389X2201 Start Date*: 2020-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar...
    Medical condition: Chronic pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005461-13 Sponsor Protocol Number: CLEE011X2106 Start Date*: 2013-10-12
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metas...
    Medical condition: estrogen receptor positive, Her2- locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004674-42 Sponsor Protocol Number: GS-US-334-1113 Start Date*: 2015-11-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005042-66 Sponsor Protocol Number: D1680C00019 Start Date*: 2017-11-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and ...
    Medical condition: Diabetes Mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004986-18 Sponsor Protocol Number: DS8201-A-U201 Start Date*: 2017-11-08
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refrac...
    Medical condition: Unresectable/metastatic breast cancer with HER2 positive expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003169-82 Sponsor Protocol Number: rAd-IFN-MM-301 Start Date*: 2019-01-30
    Sponsor Name:Trizell Ltd
    Full Title: A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003581-27 Sponsor Protocol Number: CA209-9UT Start Date*: 2020-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Ca...
    Medical condition: BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003983-10 Sponsor Protocol Number: BGB-A317-208 Start Date*: 2018-05-10
    Sponsor Name: BeiGene Ltd., c/o BeiGene USA, Inc.
    Full Title: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular U...
    Medical condition: Previously Treated Unresectable Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 343  344  345  346  347  348  349  350  351  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 17:46:21 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA